北京博晖创新生物技术集团股份有限公司 2023 年第三季度报告 证券代码：300318 证券简称：博晖创新 公告编号：临 2023-051 北京博晖创新生物技术集团股份有限公司 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 北京博晖创新生物技术集团股份有限公司 2023年第三季度报告 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增減 | | 营业收入(元) | 279.191.923.6 ...

证券代码:300318 证券简称:博晖创新 | --- | --- | --- | |------------|-------------------------------|---------| | | | 2023-04 | | | 特定对象调研 | | | 投资者关系 | □媒体采访 | | | 活动类别 | □新闻发布会 | | | | □现场参观 | | | | □其他(请文字说明其他活动内容) | | | 参与单位名 | | | | 称及人员姓 | 易方达基金管理有限公司 | | 名 时间 2023 年 9 月 19 日 11:00-12:00 地点 线上会议 上市公司接 待人员姓名 董事、副总经理、董事会秘书 董海锋先生 1、可以介绍一下公司吗? 答:公司于 2012 年 5 月 23 日上市,到目前为止,主要有两 大主营业务,分别是检验检测业务和血液制品业务。检验检测业 务近几年营收基本保持平稳状态。血液制品是公司近几年重点发 投资者关系 展的领域。自 2015 年进入血液制品行业之后,陆续加大投入。目 活动主要内 前公司有三家血液制品牌照,15 家在运营浆站,分别分布在河北 容介绍 6 家、 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 526.91 million, representing a 37.46% increase compared to CNY 383.31 million in the same period last year[24]. - The net profit attributable to shareholders was CNY 5.93 million, a significant turnaround from a loss of CNY 19.78 million in the previous year, marking a 129.96% increase[24]. - The net cash flow from operating activities reached CNY 80.39 million, a remarkable increase of 499.75% compared to a negative cash flow of CNY 20.11 million in the same period last year[24]. - The basic earnings per share improved to CNY 0.0073, compared to a loss of CNY 0.0242 per share in the previous year, reflecting a 130.17% increase[24]. - The total assets at the end of the reporting period were CNY 3.88 billion, a slight decrease of 0.61% from CNY 3.91 billion at the end of the previous year[24]. - The net assets attributable to shareholders increased by 0.52% to CNY 1.40 billion from CNY 1.39 billion at the end of the previous year[24]. - The weighted average return on net assets improved to 0.42%, up from -2.05% in the previous year[24]. - The company reported a net profit excluding non-recurring gains and losses of CNY 5.22 million, compared to a loss of CNY 21.26 million in the same period last year, representing a 124.57% increase[24]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[45]. - The company has outlined a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 1.32 billion RMB[45]. Business Segments - The company's main business segments include inspection testing and biological products[32]. - In the reporting period, the inspection testing business generated revenue of 133.75 million yuan, a decrease of 0.3% year-on-year[37]. - Revenue from in vitro diagnostic products was 85.02 million yuan, down 1.84% compared to the previous year[37]. - Revenue from non-medical testing products increased by 2.5% to 48.73 million yuan[37]. - The company’s main medical testing products include human trace element testing and HPV testing, targeting hospitals and third-party testing institutions[38]. Product Development and Innovation - The company is focused on expanding its product line in the medical device sector, particularly in immunoassay and atomic absorption technologies[40]. - The company is investing in R&D for advanced diagnostic technologies, with a focus on quantum dot fluorescence immunoassay methods, aiming to enhance testing accuracy and efficiency[46]. - The company is developing a nucleic acid chip detection instrument (Class II) for qualitative detection of 24 types of human papillomavirus, with a registration valid until November 26, 2028[42]. - The company has a new product for detecting respiratory viruses (Class III), which is intended for qualitative detection of influenza A and B viruses, with a registration expiring on February 28, 2026[42]. - The company’s total IgE antibody testing kit is expected to be launched by July 27, 2027, utilizing quantum dot immunofluorescence technology[48]. - The company is developing a fully automated nucleic acid detection analysis system, expected to be registered by May 30, 2028, for qualitative detection of target nucleic acids[48]. Market Expansion and Strategy - Market expansion plans include entering three new international markets by the end of 2024, targeting a 25% increase in international sales[45]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 200 million RMB allocated for potential mergers and acquisitions in 2024[45]. - The company aims to increase its market share in the diagnostic sector by 5% over the next year through aggressive marketing strategies and partnerships[45]. - The company is actively pursuing market expansion, with plans to enter three new provinces by Q4 2023, aiming for a 10% market share in these regions[172]. Quality Management and Compliance - The company has not identified any significant risk factors that could adversely affect its operational, financial, or profitability status[4]. - The company emphasizes quality management, having achieved certifications for medical device GMP, ISO13485, and ISO9001, ensuring high-quality product supply[64]. - The company has established a comprehensive quality management system to mitigate potential risks related to product safety, particularly in blood products[97]. Environmental Responsibility - The company is committed to sustainability and environmental responsibility, as evidenced by its ongoing projects and compliance with environmental regulations[138]. - The company has a wastewater treatment capacity of 400 tons per day, utilizing a comprehensive treatment process including neutralization, sedimentation, A/O, MBR, and disinfection with hypochlorous acid[143]. - The company has implemented upgrades to its wastewater treatment facilities, enhancing compliance with environmental regulations[136]. - The company has established internal wastewater treatment facilities to handle industrial wastewater generated during operations[140]. - The company has a monitoring system for wastewater with various parameters, including a maximum limit of 500 mg/L for fecal coliform bacteria, monitored quarterly[157]. Shareholder and Governance Matters - The annual shareholders' meeting had a participation rate of 45.47% on June 29, 2023[105]. - No cash dividends or stock bonuses were distributed for the half-year period, and no capital reserve was converted into share capital[108]. - The company appointed new directors and management on June 29, 2023, including a new chairman and several non-independent directors[106]. - The company has maintained a clean record with no significant litigation or arbitration matters reported in the first half of 2023[179]. Financial Management - The company has no significant related party transactions during the reporting period, ensuring transparency in operations[181][183]. - The company has no significant guarantees or collateral obligations reported, maintaining a conservative financial position[195]. - The company reported a total of 30 million yuan in claims related to a lawsuit that is still in the filing stage[184]. - The company has ongoing significant contracts that may impact its financial performance[200].

证券代码：300318 证券简称：博晖创新 | --- | |------------| | | | 投资者关系 | | 活动类别 | | | | | | 参与单位名 | | | | 称及人员姓 | | | | 名 | 时间 2023 年 7 月 13 日 10:00-11:00 地点 公司会议室 上市公司接 待人员姓名 董事、副总经理、董事会秘书 董海锋先生 1、公司目前有几个血液制品牌照，血液制品板块未来布局/计 划？ 答：公司目前有 3 个血液制品生产企业，分别是位于河北石 家庄的博晖生物制药（（河北）有限公司（（（ 河北博晖"），位于河北 投资者关系 廊坊的博晖生物制药股份有限公司（（（ 廊坊博晖"），以及位于广东 活动主要内 汕头的广东卫伦生物制药有限公司（（（ 广东卫伦"）。另外，公司已 容介绍 经在云南曲靖投资建成了 1500 吨加工能力的血制生产工厂，目前 正在进行血制生产资质迁址至云南工厂的相关工作。同时，为了 拓展血浆资源和市场区域，在内蒙古呼和浩特筹建了一个新的血 液制品生产工厂，未来待内蒙古工厂建成后，计划将旗下的一个 血制生产资质迁至内蒙古工厂。 北京博晖创新生物技术集团股份有限公司 ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 | --- | --- | |------------|---------------------------------| | | 特定对象调研 | | 投资者关系 | □媒体采访 | | 活动类别 | □新闻发布会 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名 | | | | 国金证券股份有限公司 | | 称及人员姓 | | | | 农银汇理基金管理有限公司 | 名 时间 2023 年 6 月 26 日 15:00-16:00 地点 公司会议室 上市公司接 待人员姓名 董事、财务总监兼董事会秘书 董海锋先生 1、能简单介绍一下大股东情况吗？ 答：公司大股东是杜江涛先生，持有本公司 39.03%股份。另 外，杜江涛先生也持有另一家上市公司君正集团（股票代码： 601216）31.95%股份。 投资者关系 2、公司血液制品业务主要依靠哪些资源发展？ 活动主要内 答：公司自进入血液制品业务以来，在产品研发、浆站拓展方 容介绍 面进行了持续投入，并获得了一定成效，产 ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------|---------------------------------|---------| | | | 2023-01 | | | □特定对象调研 | | | 投资者关系 | □媒体采访 | | | 活动类别 | □新闻发布会 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名 | | | | 称及人员姓 | 线上参与公司 2022 | | 名 时间 2023 年 5 月 10 日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事长 沈治卫先生 上市公司接 独立董事 班均先生 待人员姓名 董事、财务总监兼董事会秘书 董海锋先生 1、请问沈董事长，中科生物生产设备进行升级改造进展如 何？何时能恢复正常生产？ 答：中科生物维修改造正按照计划积极推进中，目前正在按 投资者关系 照监管法规要求进行信息化改造，后续需政府相关部门进行验收， 活动 ...

Financial Performance - The company's revenue for Q1 2023 was ¥252,950,995.14, representing a 44.22% increase compared to ¥175,394,242.89 in the same period last year[5] - Net profit attributable to shareholders was ¥5,174,206.08, a significant turnaround from a loss of ¥13,243,101.60 in Q1 2022, marking a 139.07% increase[5] - Basic earnings per share rose to ¥0.0063 from a loss of ¥0.0162, indicating a 138.89% improvement[5] - Total operating revenue for Q1 2023 was CNY 252,950,995.14, an increase of 44.4% compared to CNY 175,394,242.89 in Q1 2022[28] - Net profit for Q1 2023 reached CNY 9,672,620.16, a significant recovery from a net loss of CNY 26,680,596.65 in Q1 2022[29] - The company reported a gross profit margin of approximately 4.9% for Q1 2023, compared to a negative margin in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 9,156,153.67, compared to a loss of CNY 26,934,387.20 in the same period last year[30] Cash Flow and Financial Position - The net cash flow from operating activities improved to ¥5,173,217.62, compared to a negative cash flow of ¥29,404,292.88 in the previous year, reflecting a 117.59% increase[5] - The company reported a decrease in cash and cash equivalents to ¥93,007,540.49 from ¥113,600,046.91 at the beginning of the year, representing a decline of approximately 18.3%[22] - The company’s cash and cash equivalents were CNY 1,103,368,335.50, down from CNY 1,140,130,256.34 in the previous year[24] - The net cash flow from financing activities was CNY 39,680,216.45, a decrease from CNY 132,357,092.92 in the previous year[34] - The company incurred cash outflows from investing activities totaling CNY 65,391,879.04, compared to CNY 37,529,195.84 in the same period last year[34] - The company received CNY 311,022,700.66 in cash from borrowings, significantly higher than CNY 68,000,000.00 in the previous year[34] - The total cash inflow from financing activities was CNY 693,022,700.66, compared to CNY 237,100,000.00 in the same period last year[34] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,883,039,678.80, a slight decrease of 0.64% from ¥3,908,002,277.01 at the end of the previous year[5] - Total liabilities decreased to CNY 1,550,004,592.03 in Q1 2023 from CNY 1,584,123,343.91 in Q1 2022[25] - The company’s equity attributable to shareholders increased to CNY 1,398,188,443.27 from CNY 1,393,532,991.70 year-over-year[26] Operational Highlights - The company experienced a 40.62% increase in cash received from sales, totaling ¥258,419,243.49, driven by growth in blood product sales[12] - The company reported a 715.48% increase in other income, amounting to ¥1,781,470.44, primarily due to increased government subsidies received[10] - The company’s financial expenses decreased by 50.34% to ¥6,238,699.81, attributed to a reduction in short-term debt[10] - Revenue from sales of goods and services received cash of CNY 258,419,243.49, up from CNY 183,767,004.44 in the prior year[32] Shareholder Information - Major shareholder Du Jiangtao holds 39.03% of the shares, totaling 318,811,388 shares[15] - The company has a total of 20,001,720 shares under lock-up, with 178,500 shares released during the period[18] - The company’s vice president reduced her holdings by 179,000 shares at an average price of ¥6.1128 per share, accounting for 0.0219% of the total share capital[19] Investments and Development - The company’s cash outflow for the purchase of fixed assets increased by 74.43% to ¥65,391,879.04, reflecting ongoing investments in the Yunnan blood product project[12] - The company provided guarantees totaling up to ¥650 million for its subsidiaries, with ¥250 million specifically allocated for financing through a cloud platform[20] - The company’s subsidiary obtained a single plasma collection license from the Yunnan Provincial Health Commission[20] - Research and development expenses for Q1 2023 were CNY 14,197,200.03, slightly up from CNY 13,783,836.86 in Q1 2022[29] Receivables and Inventory - Accounts receivable decreased to ¥65,251,577.57 from ¥75,921,242.82, a reduction of about 13.9%[23] - Inventory slightly decreased to ¥860,199,805.87 from ¥870,516,782.75, indicating a decrease of approximately 1.4%[23] - The company’s total receivables from financing decreased to ¥3,120,031.32 from ¥6,485,146.87, a decline of approximately 51.8%[23] - The company’s prepayments increased to ¥15,106,599.30 from ¥8,255,312.80, reflecting an increase of about 83.3%[23]

Financial Performance - The company reported a total revenue of 816.9 million RMB for the year 2022, with no cash dividends distributed to shareholders[5]. - The company's operating revenue for 2022 was ¥795,932,495.41, an increase of 11.36% compared to ¥714,748,462.45 in 2021[20]. - The net profit attributable to shareholders was -¥78,325,488.76, showing a 75.69% improvement from -¥322,176,629.03 in 2021[20]. - The cash flow from operating activities reached ¥40,718,935.07, a significant increase of 4,486.61% compared to ¥887,777.88 in 2021[20]. - The total assets at the end of 2022 amounted to ¥3,908,002,277.01, reflecting a 5.91% increase from ¥3,690,026,740.04 at the end of 2021[20]. - The net assets attributable to shareholders increased by 42.96% to ¥1,393,532,991.70 from ¥974,752,736.01 in 2021[20]. - The company reported a basic and diluted earnings per share of -¥0.0959, improving by 75.68% from -¥0.3944 in 2021[20]. - The company's revenue after deducting non-recurring items was ¥751,603,420.53, up from ¥682,179,143.93 in 2021[21]. - The company’s non-recurring gains totaled ¥17,248,995.25 in 2022, compared to ¥14,891,931.39 in 2021[27]. - The revenue from the biological products segment was ¥503.41 million, accounting for 63.25% of total revenue, with a year-on-year growth of 31.52%[84]. - The revenue from the testing and inspection segment was ¥248.20 million, which represented a decline of 17.11% year-on-year[84]. - The company achieved a gross margin of 15.67% in the biological products segment, which decreased by 9.42% compared to the previous year[87]. - The total revenue for the company in 2022 was approximately ¥795.93 million, representing an increase of 11.36% compared to ¥714.75 million in 2021[84]. Market Position and Strategy - The company maintains a strong commitment to research and development in microfluidic chip technology and molecular diagnostics[13]. - The company is focused on expanding its product offerings based on its existing technology platform to enhance its market presence[39]. - The company is a leader in the trace element detection market, with a stable user base and established products in hospitals[39]. - The company has established a stable partnership with multiple distributors across the country, enhancing its market position through innovative technology and customer network[54]. - The company aims to enhance its market presence through the development of innovative medical devices and technologies[59]. - The company is focused on expanding its operations in the biopharmaceutical market, with plans for potential mergers and acquisitions to enhance its competitive position[180]. - The company is actively pursuing new strategic investments in the blood products sector to enhance its market position[79]. - The company aims to enhance its blood product business by increasing operational efficiency and expanding its market presence over the next 3-5 years[133]. Product Development and Innovation - The company is committed to continuous innovation in the field of medical diagnostics, with multiple products in the pipeline for the next few years[62]. - The company is developing several new diagnostic products, including a high-risk HPV test kit and a respiratory pathogen test kit, aiming for market competitiveness[97]. - The company has developed a series of diagnostic kits for measuring various elements in human blood, including copper, zinc, calcium, magnesium, and iron, with expected launch dates in July 2024[62]. - The company plans to launch a series of new diagnostic kits, including the Procalcitonin Test Kit and the 25-Hydroxyvitamin D Test Kit, with expected registration dates in March 2025[63]. - The company is expanding its product line with a new C-reactive protein testing kit, expected to launch in March 2025, to assess inflammation levels[62]. - The company is focusing on enhancing its diagnostic capabilities through the introduction of quantum dot fluorescence immunoassay methods for various tests[62]. - The Quantum Dot Fluorescence Immunoassay technology is expected to improve the accuracy and efficiency of diagnostic testing[63]. - The company has developed over 20 patents related to its microfluidic chip molecular diagnostic platform, establishing a competitive edge in the automated molecular diagnostic field[76]. Regulatory Compliance and Governance - The company emphasizes its dedication to compliance with regulatory standards set by the China Securities Regulatory Commission[11]. - The company’s blood product offerings comply with strict regulatory policies, which pose challenges for market entry[47]. - The company has passed certifications for medical device GMP, ISO13485, and ISO9001, ensuring high-quality product management[80]. - The company maintains a strict governance structure, ensuring independence from its controlling shareholder in terms of assets, personnel, finance, and operations[159]. - The company has established an independent financial accounting system and management practices, ensuring compliance with relevant laws and regulations[163]. - The company has a dedicated investor relations management system to foster good interactions with investors and maintain a positive image in the capital market[157]. Human Resources and Management - The total number of employees at the end of the reporting period was 1,773, with 299 in the parent company and 1,474 in major subsidiaries[196]. - The company employed 933 technical personnel, 343 production staff, and 197 sales personnel, indicating a strong focus on technical expertise[196]. - The educational background of employees included 24 with doctoral degrees, 50 with master's degrees, and 556 with bachelor's degrees, reflecting a highly educated workforce[196]. - The company implemented a competitive compensation policy to attract and retain talent, ensuring alignment with market standards[198]. - Employee benefits included annual health check-ups, supplemental medical insurance, and various welfare programs to enhance employee satisfaction and loyalty[198]. - The company has maintained a stable management team with no significant changes in senior management positions[171]. - The financial director, Dong Haifeng, has extensive experience in investment management and financial oversight, contributing to the company's financial health[181]. Challenges and Risks - The company is facing risks related to the slow progress of key projects, particularly the resumption of production at Zhongke Biological and the migration of production qualifications for the Yunnan blood product project, which require government approvals[144]. - Continuous investment in R&D, fixed assets, and market promotion has led to a tight financial situation, necessitating increased fundraising efforts to meet business development needs[145]. - The company has established a comprehensive quality management system to address potential risks related to product safety and regulatory compliance[141]. - The company is committed to ensuring product safety and quality control to mitigate risks associated with blood products[140]. Sales and Marketing - The company’s main business revenue from inspection and testing reached 248.2 million yuan, a year-on-year decrease of 17.11%, with medical testing products generating 140.96 million yuan, down 30.22%[55]. - The sales volume of blood products increased by 45.62% year-on-year, with significant contributions from intravenous immunoglobulin and human albumin[90]. - The company’s strategy includes expanding its market presence through competitive pricing and new sales channels, as evidenced by its procurement successes[68]. - The company achieved a sales volume of 527,958 bottles of intravenous immunoglobulin, marking a 35.51% increase from 389,602 bottles in the previous year[70]. Shareholder and Board Information - The annual shareholders meeting had a participation rate of 42.53%[166]. - The company reported a total of 26,906 shares held by directors and supervisors at the end of the reporting period[169]. - The chairman of the board, Zhai Xiaofeng, resigned on May 31, 2022, due to personal reasons[170]. - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and decision-making processes[152]. - The total remuneration for directors, supervisors, and senior management amounted to 5.5753 million yuan[188].